Geode Capital Management
AUTL

Geode Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Geode Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$198K Buy
123,934
+13,356
+12% +$21K ﹤0.01% 3919
2026
Q1 		$153K Hold
110,578
– – ﹤0.01% 4012
2025
Q4 		$220K Sell
110,578
-53,736
-33% -$82.6K ﹤0.01% 3867
2025
Q3 		$268K Hold
164,314
– – ﹤0.01% 3835
2025
Q2 		$375K Buy
164,314
+78,058
+90% +$129K ﹤0.01% 3645
2025
Q1 		$134K Hold
86,256
– – ﹤0.01% 3949
2024
Q4 		$203K Hold
86,256
– – ﹤0.01% 3904
2024
Q3 		$313K Hold
86,256
– – ﹤0.01% 3752
2024
Q2 		$300K Hold
86,256
– – ﹤0.01% 3766
2024
Q1 		$550K Hold
86,256
– – ﹤0.01% 3577
2023
Q4 		$555K Hold
86,256
– – ﹤0.01% 3566
2023
Q3 		$201K Sell
86,256
-26,689
-24% -$76K ﹤0.01% 3979
2023
Q2 		$269K Buy
112,945
+59,209
+110% +$140K ﹤0.01% 3909
2023
Q1 		$98.9K Hold
53,736
– – ﹤0.01% 4340
2022
Q4 		$102K Sell
53,736
-79,702
-60% -$202K ﹤0.01% 4396
2022
Q3 		$285K Hold
133,438
– – ﹤0.01% 4016
2022
Q2 		$377K Hold
133,438
– – ﹤0.01% 3910
2022
Q1 		$556K Sell
133,438
-65,047
-33% -$274K ﹤0.01% 3883
2021
Q4 		$1.03M Buy
198,485
+135,956
+217% +$816K ﹤0.01% 3708
2021
Q3 		$409K Buy
62,529
+14,367
+30% +$90.8K ﹤0.01% 4127
2021
Q2 		$319K Buy
48,162
+32,379
+205% +$201K ﹤0.01% 4138
2021
Q1 		$90K Hold
15,783
– – ﹤0.01% 4323
2020
Q4 		$141K Sell
15,783
-4,160
-21% -$44.3K ﹤0.01% 3989
2020
Q3 		$232K Hold
19,943
– – ﹤0.01% 3674
2020
Q2 		$319K Hold
19,943
– – ﹤0.01% 3522
2020
Q1 		$119K Buy
19,943
+798
+4% +$7.38K ﹤0.01% 3710
2019
Q4 		$252K Buy
19,145
+7,813
+69% +$102K ﹤0.01% 3721
2019
Q3 		$140K Hold
11,332
– – ﹤0.01% 3878
2019
Q2 		$182K Buy
11,332
+1,521
+16% +$34K ﹤0.01% 3814
2019
Q1 		$308K Hold
9,811
– – ﹤0.01% 3603
2018
Q4 		$322K Buy
+9,811
New +$323K ﹤0.01% 3531

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management's AUTL Position: Q2 2026 in Review

Geode Capital Management increased its Autolus Therapeutics (AUTL) stake by 12% in Q2 2026, buying an estimated $21K and bringing the position to 123,934 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #3919.

Geode Capital Management first reported a position in AUTL in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.03M in Q4 2021. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Geode Capital Management held 123,934 shares of Autolus Therapeutics worth $198K as of Q2 2026.
  • Geode Capital Management bought 13,356 Autolus Therapeutics shares in Q2 2026, an estimated $21K.
  • Autolus Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3919 holding.
  • Geode Capital Management first reported a position in Autolus Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • Geode Capital Management's Autolus Therapeutics position peaked at $1.03M in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.